Pharma multinational GlaxoSmithKline (GSK.NYSE, GSK.LON) appointed a senior figure from within the company as head of China operations amid a probe into corrupt practices at the company, The Wall Street Journal reported. Herve Gisserot, co-head of the British drug maker’s pharmaceutical business in Europe, is replacing Mark Reilly as general manager in China. Reilly remains with GSK in London, where he will help lead the company’s response to the Chinese government’s bribery investigation, a spokesman said. Separately, a US citizen arrested by Chinese officials in relation to the GSK case is the wife of a British fraud investigator also being held, Reuters reported, citing unnamed sources.
You must log in to post a comment.